Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Oppenheimer initiated coverage on Vaxart, highlighting its oral vaccine potential. The analyst set a $4 price target, indicating significant upside for VXRT. Vaxart leads in developing an oral vaccine for norovirus, addressing unmet needs. BARDA funding supports VXRT's COVID-19 vaccine development and potential market impact. The company's oral vaccine may enhance immunity compared to traditional methods.
- Oppenheimer initiated coverage on Vaxart, highlighting its oral vaccine potential.
- The analyst set a $4 price target, indicating significant upside for VXRT.
- Vaxart leads in developing an oral vaccine for norovirus, addressing unmet needs.
- BARDA funding supports VXRT's COVID-19 vaccine development and potential market impact.
- The company's oral vaccine may enhance immunity compared to traditional methods.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.